Today's News | Note: News feeds may no longer be available for the articles on this page.

Bayer sells rights to leukaemia drug to Genzyme 6:49 AM 3/31/2009
Reuters - USA
Bayer AG agreed to sell the rights to its leukemia drug Campath and two more hematological cancer treatments to Genzyme. ...

Sepracor submits new drug application 6:46 AM 3/31/2009
Boston Globe - United States
Sepracor Inc has submitted a new drug application to the US FDA for the use of Stedesa (eslicarbazepine acetate) as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. ...

Ipsen wins anti-wrinkle drug go-ahead in France 5:23 AM 3/31/2009
Reuters - USA
Ipsen and partner Galderma have won French marketing approval for anti-wrinkle treatment Azzalure. They're awaiting approval in the US where it will be distributed by Medicis Pharmaceutical Corp under the name Reloxin competing with Allergan's Botox.

Japan's biggest drug maker Takeda Pharmaceutical to move R&D base ... 2:28 AM 3/31/2009
Los Angeles Times - CA,USA
Takeda Pharmaceutical Co will move its global research and development headquarters to Illinois. Takeda seeks to boost its global operations and introduce new products ahead of the 2011 patent expiration of hit diabetes drug Actos. ...

AstraZeneca drug may help brain tumors: study 5:09 PM 3/30/2009
Reuters - USA
AstraZeneca Plc's cancer drug Recentin (cediranib) may help fight the deadly effects of brain tumors without shrinking them. The drug helped stop the fluid build-up caused by glioblastoma. ...

FDA approves new drug for deadly kidney cancer 3:30 PM 3/30/2009
The Associated Press
The US FDA says cancer patients receiving Novartis' Afinitor lived over twice as long without tumor growth as patients not receiving the drug. Kidney cancer is usually fatal within five years killing about 13,000 people each year. ...

House Panel to Take Up Generic-Drug Measure 2:13 PM 3/30/2009
Wall Street Journal - USA
A bill banning makers of brand-name pharmaceuticals from paying to delay generic drugs from hitting the market has the support of key lawmakers ahead of a House subcommittee hearing. ...

FDA: Few Cardiovascular Events With Saxagliptin 12:47 PM 3/30/2009
Wall Street Journal - USA
The Bristol-Myers Squibb and AstraZeneca proposed diabetes drug saxagliptin demonstrates a low cardiovascular event rate in clinical studies. ...

One pill for heart-attack prevention? 12:03 PM 3/30/2009
Los Angeles Times - CA,USA
People have trouble taking several heart drugs each day. A new study looks at the "polypill" that contains multiple drugs in one capsule. ...

GSK submits data for US cancer vaccine 9:54 AM 3/30/2009
Forbes - NY,USA
GlaxoSmithKline PLC submitted final data to support its application to market cervical cancer vaccine Cervarix in the US. ...

Arena obesity drug disappoints; shares fall 8:27 AM 3/30/2009P
Reuters - USA
Arena Pharmaceuticals' experimental obesity drug helped patients shed only about 10 pounds more than those taking placebo. ...

Cadila Health Signs Drug Devt Pact With Eli Lilly 6:29 AM 3/30/2009
CNNMoney.com - USA
Cadila Healthcare Ltd signed a pact with Eli Lilly & Co to discover and develop drugs to treat cardiovascular disease. Lilly has entered similar pacts with Piramal Life Sciences Ltd, Jubilant Organosys Ltd, and Suven Life Sciences Ltd. . ...

Glaxo, Sanofi eyeing India's Shantha Biotech - paper 4:12 AM 3/30/2009
Reuters India - Mumbai,India
Glaxo and Sanofi called the report speculative. Shantha's management is not aware of any sale discussions, but claims to be the first Indian company to develop, manufacture, and market a recombinant healthcare product in India. ...

Abbott, Astra drug combo works in cholesterol study 5:42 PM 3/29/2009
Reuters - USA
Abbott Laboratories' new TriLipix triglycerides drug combined with a low dose of AstraZeneca's Crestor proved better than the individual pills in helping improve heart risk factors. ...

Eli Lilly schizophrenia drug trial inconclusive 2:22 PM 3/29/2009
Reuters - USA
Eli Lilly and Co will initiate another mid-stage trial to study an experimental schizophrenia drug after results from its initial Phase II trial were inconclusive. ...

<- Day Earlier | Today's News